Myocardial Infarction Size Reduction With Atorvastatin
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00286312|
Recruitment Status : Completed
First Posted : February 3, 2006
Last Update Posted : May 21, 2008
|Condition or disease||Intervention/treatment||Phase|
|Myocardial Infarction Reperfusion Injury||Drug: Atorvastatin||Phase 4|
Left ventricular remodelling after a myocardial infarction refers to changes in shape and function of the infarcted and uninfarcted myocardium. Remodelling begins minutes after acute myocardial infarction and may continue for months or years, leading to dilation of the left ventricle (LV) and an increased LV volume. As studies show, LV volume strongly correlates with long-term mortality. Reperfusion after a period of ischaemia (through medication or PTCA) leads to so-called 'reperfusion injury'. This results in myocardial dysfunction and damage, which can lead to LV remodelling.
In a study where atorvastatin was administered at the onset of reperfusion infarct size was reduced. Atorvastatin led to protection of the reperfused myocardium, independently of its effects on cholesterol.
The objective is to measure the effect of atorvastatin, administered orally before reperfusion therapy by PTCA, on infarct size and microvascular reperfusion.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Prevention of Reperfusion Damage and Late Left Ventricular Remodelling With Atorvastatin Administered Before Reperfusion Therapy. The REPERATOR Study|
|Study Start Date :||February 2006|
|Actual Primary Completion Date :||February 2008|
|Actual Study Completion Date :||February 2008|
- Left ventricular end systolic volume index as measured by cine magnetic resonance imaging (MRI) at 3 month follow-up
- Other MRI measurements of global and regional left ventricular function
- MRI measurements of infarct size at admission, 1 week, and 3 months, as well as changes in these measures between MRI investigations
- Biochemical markers of infarct size
- Blush grade
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00286312
|St. Antonius Hospital|
|Nieuwegein, Netherlands, 3435CM|
|University Medical Centre Utrecht|
|Principal Investigator:||Benno Rensing, MD, PhD||St. Antonius Ziekenhuis Nieuwegein|